BioCentury
ARTICLE | Clinical News

APTO-253: Development delayed

February 3, 2017 5:35 PM UTC

Aptose said it will “temporarily delay clinical activities” for its IV APTO-253 to allow the company to investigate the cause of manufacturing issues. Aptose said it will prioritize its resources on preclinical cancer candidate CG026806 (CG’806) due to the delay and evidence of CG’806’s “unique activity profile.” CG’806 is a once-daily oral small molecule inhibitor of Bruton’s tyrosine kinase (Btk), FMS-like tyrosine kinase 3 (FLT3; CD135) and Aurora kinases...

BCIQ Company Profiles

Aptose Biosciences Inc.